肾复康胶囊联合阿魏酸钠治疗慢性肾小球肾炎的临床研究

Clinical study on Shenfukang Capsules combined with sodium ferulate in treatment of chronic glomerulonephritis

目的探讨肾复康胶囊联合注射用阿魏酸钠治疗慢性肾小球肾炎的临床疗效。方法选取2015年1月—2016年1月在成都新华医院肾内科接受治疗的72例慢性肾小球肾炎患者,采用计算机法随机分为对照组和治疗组,每组各36例。对照组静脉滴注注射用阿魏酸钠,0.3 g加入到5%葡萄糖注射液250 m L中,1次/d。治疗组在对照基础上口服肾复康胶囊,1.5 g/次,3次/d。两组患者均连续治疗1个月。观察两组患者的临床疗效,比较两组治疗前后血肌酐(Scr)、血尿素氮(BUN)、24 h尿蛋白量(24 h Upro)、红细胞(RBC)、β2-MG以及血清中组织型纤溶酶原激活剂(t-PA)、纤溶酶原激活抑制物-1(PAI-1)水平。结果治疗后,对照组、治疗组的总有效率分别为77.78%、94.44%,两组总有效率比较差异具有统计学意义(P<0.05)。治疗后,两组患者Scr、BUN、24 h Upro、RBC、β2-MG均较治疗前明显降低,同组治疗前后差异具有统计学意义(P<0.05);且治疗组这些观察指标的降低程度优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清t-PA水平明显升高,PAI-1水平明显降低,同组治疗前后差异具有统计学意义(P<0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P<0.05)。结论肾复康胶囊联合注射用阿魏酸钠治疗慢性肾小球肾炎的临床疗效显著,不仅可以改善患者肾功能,还能升高血清t-PA水平,降低血清PAI-1水平以及降低尿蛋白,有利于慢性肾小球肾炎患者症状改善,具有一定的临床推广应用价值。

Objective To investigate the effect of Shenfukang Capsules combined with Sodium Ferulate for injection in treatment of chronic glomerulonephritis. Methods Patients （72 cases） with chronic glomerulonephritis in Department of Neurology of Chengdu Xinhua Hospital from 2015 January to 2016 January were randomly divided into control and treatment groups using the computer method, and each group had 36 cases. The patients in the control group were iv administered with Sodium Ferulate for injection, 0.3 g added into 5% glucose Injection 250 mL, once daily. The patients in the treatment group were po administered with Shenfukang Capsules on the basis of control group, 1.5 g /time, three times daily. The patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the changes of Scr, BUN, 24 h urine protein, RBC, and β2-MG, and levels of t-PA and PAI-1 in serum before and after treatment in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.52% and 94.44%, respectively, and there were differences between two groups （P 〈 0.05）. After treatment, Scr, BUN, 24 h Upro, RBC, and β2-MG in two groups were significantly decreased, and the difference was statistically significant in the same group （P 〈 0.05）. After treatment, the observational indexes in the treatment group were significantly decreased than those in the control group, with significant difference between two groups （P 〈 0.05）. After treatment, levels of t-PA in two groups were significantly increased, PAI-1 was significantly decreased, and the difference was statistically significant in the same group （P 〈 0.05）. After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups （P 〈 0.05）. Conclusion Shenfukang Capsules combined with Sodium Ferulate for injection has clinical curative effect in treatment of chronic glomerulonephritis, not only can improve renal function in patients, but also can elevate the level of serum t-PA, decrease the levels of PAI-1, and decrease urinary protein, is beneficial to improve symptoms in patients with chronic glomerulonephritis, which has a certain clinical application value.